Senti Biosciences (SNTI) Proxy Filing summary

Executive summary

• Special Meeting of Stockholders scheduled for March 6, 2025, to be held virtually, with voting on three key proposals.

• Proposals include approval of stock issuance related to a recent private placement, amendment of the 2022 Equity Incentive Plan, and potential adjournment if votes are insufficient.

• The private placement in December 2024 raised $47.6 million through Series A Preferred Stock and warrants, with potential for significant dilution upon conversion.

• Board recommends voting in favor of all proposals.

Voting matters and shareholder proposals

• Proposal 1 seeks approval for issuance of common stock upon conversion of Series A Preferred Stock and exercise of warrants, potentially exceeding 20% of outstanding shares and triggering Nasdaq change of control rules.

• Proposal 2 requests an increase of 4,300,000 shares to the 2022 Equity Incentive Plan, raising the ISO limit and extending the plan's term by 10 years.

• Proposal 3 allows adjournment of the meeting to solicit more votes if needed.

• All proposals require a majority of votes cast for approval; abstentions and broker non-votes have no effect.

Board of directors and corporate governance

• Board is authorized to issue up to 10,000,000 shares of preferred stock and can fill board vacancies by majority vote.

• Directors serve staggered three-year terms, and removal requires a 75% supermajority.

• Anti-takeover provisions include advance notice for nominations, no cumulative voting, and exclusive forum selection for certain legal actions.